How AI is making its way into pharma and healthcare
Will we see enhancements of AI in pharma and healthcare? Having read many insightful articles and spoken to several experts on how artificial intelligence (AI)...
Brexit and the UK life science industry
Damon Culbert looks at Brexit and the UK life science industry with particular consideration to the impact of immigration. For many industry professionals, Britain’s plans to leave the European...
High Court ruling against Novartis and Bayer: Implications
Claudia Rubin and Tom Jaggs explore the implications of the High Court ruling against Novartis and Bayer for pharma.
High Court ruling against Novartis and...
NHS long-term plan: Growing importance of prevention medicine
“The challenge now is for the NHS to respond to this changing landscape and to focus on preventing as well as treating the conditions...
Have analytics been relegated to a reporting function?
Have business analytics been pushed to the background? Business information upgraded, smart CRM datasets, the Predictive Analytics silver bullet and other fairy tales.
Is Brexit good news for pharma?
James Burt, Executive Vice President EMENA, Accord Healthcare, asks whether Brexit will in fact present an opportunity for positive change in pharma and healthcare.
What do NHS changes mean for tech innovation?
Could changes at the top mean fresh opportunities for tech innovation?
Read this in the August issue of Pf Magazine.
For some time it has been...
At the heart of it: The vital role of pharmacies in community health
Read this in the August issue of Pf Magazine.
Community pharmacy has a clear role in promoting and supporting the public’s health. There’s an accessible...
Five ways blockchain is impacting healthcare
Blockchain is one of the most talked about technologies at the moment and boasts huge potential to transform how we deliver healthcare and revolutionise...
Brexit: What will it mean for the regulation of medicines?
What are the implications for the movement of medicines from and into the UK, post-brexit? Mark Quick, executive vice president of corporate development at Recipharm, comments on the current situation and the potential implications of the UK exiting the European Union (EU).
Latest articles
Addressing the wellbeing of doctors – new report from GMC
A new report on the wellbeing of doctors commissioned by the General Medical Council (GMC) says that UK health services could be world leaders...
Industry figures recognised as Top 100 Most Influential BAME Leaders in Tech
Industry figures have been announced as part of the #IB100 – a list of the top 100 most influential black, Asian and minority ethnic...
Lack of knowledge about type 2 diabetes risk factors – survey
An international survey published to mark World Diabetes Day shows a lack of knowledge about type 2 diabetes risk factors. The results of the...
Popular articles
Industry figures recognised as Top 100 Most Influential BAME Leaders in Tech
Industry figures have been announced as part of the #IB100 – a list of the top 100 most influential black, Asian and minority ethnic...
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Market Access in practice: do you have a strategy?
This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...
How to be a successful key account manager
Pf asked two consultants from top pharma recruitment consultancies for their views on what it takes to be a successful key account manager.
Andy Boyd, Senior...
The Twilight Zone
Classified drugs, which are potentially dangerous and liable to abuse, have legitimate uses but also turn up on the black market. What does this mean for industry – and how has the internet affected this problem?